Episode 8: ASCO 2025 Debrief: Key Updates in Genitourinary Cancer Management

Opinion
Video

Manojkumar Bupathi, MD, MS; and Benjamin Garmezy, MD, discuss abstracts from the 2025 ASCO Annual Meeting that may affect genitourinary cancer care.

As part of the latest ONCOLOGY Decoded discussion, Manojkumar Bupathi, MD, MS, met with Benjamin Garmezy, MD, after the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting to review data from the late-breaking abstracts, poster sessions, and other presentations of interest that may shift the paradigm across different genitourinary malignancies.


Bupathi is the executive cochair of the Genitourinary Cancer Research Executive Committee at Sarah Cannon Research Institute (SCRI) and medical oncologist with Rocky Mountain Cancer Centers specializing in solid tumors and genitourinary cancers. Garmezy is the associate director of genitourinary research and executive cochair of the Genitourinary Cancer Research Executive Committee at SCRI and medical oncologist at
SCRI Oncology Partners, also specializing in genitourinary cancers.


These experts highlighted their top abstracts and presentations from this year’s ASCO Annual Meeting, breaking down the results and clinical implications of key research in prostate cancer, bladder cancer, and other patient populations. Noteworthy studies and analyses included the following:

  • Phase 3 AMPLITUDE Trial (NCT04497844)1
    • Niraparib (Zejula) plus abiraterone acetate (Zytiga) with prednisone (AAP) reached the primary end point of radiographic progression-free survival, reducing the risk of radiographic progression or death by 48% (HR, 0.52; 95% CI, 0.37-0.72; P < .0001) in the BRCA-mutated metastatic castration-sensitive prostate cancer (CSPC) population and 37% (HR, 0.63; 95% CI, 0.49-0.80; P = .0001) in the homologous recombination repair (HRR)–mutated subgroup vs AAP alone.
    • The niraparib combination also improved time to symptomatic progression across the BRCA-mutant disease population (HR, 0.44; 95% CI, 0.29-0.68; P = .0001) and the HRR-mutant disease subgroup (HR, 0.50; 95% CI, 0.36-0.69; P < .0001).
    • Overall, data from AMPLITUDE appear to support early genomic testing and reinforce niraparib plus AAP as a new therapeutic option for patients with metastatic CSPC harboring HRR alterations.
  • Phase 3 NIAGARA Trial (NCT03732677)2
    • Investigators found circulating tumor DNA (ctDNA) status to be highly prognostic for outcomes among patients who received perioperative durvalumab (Imfinzi) plus neoadjuvant chemotherapy for muscle-invasive bladder cancer (MIBC).
    • Across the treatment arms in the NIAGARA trial, ctDNA-negative status conferred improvements in event-free survival vs ctDNA positivity (HR, 0.42; 95% CI, 0.30-0.60).
    • Adding nivolumab to neoadjuvant chemotherapy increased the rate of ctDNA clearance by 13% vs the use of chemotherapy alone.
  • Phase 2 SURE-02 Trial (NCT05535218)3
    • Combining perioperative sacituzumab govitecan-hziy (Trodelvy) with pembrolizumab (Keytruda) produced clinical complete responses in 44.4% (95% CI, 27.9%-61.9%) of patients with MIBC.
    • The study treatment allowed for bladder preservation without chemoradiotherapy in 74% of patients who refused radical cystectomy.
    • The data demonstrated a potentially safe and effective approach for patients with no standard-of-care options at the time of refusing radical cystectomy.

References

  1. Attard G, Agarwal N, Graff J, et al. Phase 3 AMPLITUDE trial: niraparib (NIRA) and abiraterone acetate plus prednisone (AAP) for metastatic castration-sensitive prostate cancer (mCSPC) patients (pts) with alterations in homologous recombination repair (HRR) genes. J Clin Oncol. 2025;43(suppl 17):LBA5006. doi:10.1200/JCO.2025.43.17_suppl.LBA5006
  2. Powles T, Van Der Heijden M, Wang Y, et al. Circulating tumor DNA (ctDNA) in patients with muscle-invasive bladder cancer (MIBC) who received perioperative durvalumab (D) in NIAGARA. J Clin Oncol. 2025;43(suppl 16):4503. doi:10.1200/JCO.2025.43.16_suppl.4503
  3. Necchi A, de Jong J, Proudfoot J, et al. First results of SURE-02: a phase 2 study of neoadjuvant sacituzumab govitecan (SG) plus pembrolizumab (pembro), followed by response-adapted bladder sparing and adjuvant pembro, in patients with muscle-invasive bladder cancer (MIBC). J Clin Oncol. 2025;43(suppl 16):4518. doi:10.1200/JCO.2025.43.16_suppl.4518
Recent Videos
Destigmatizing cancer care for incarcerated patients may help ensure that they feel supported both in their treatment and their humanity.
Patients with mediastinal lymph node involved-lung cancer may benefit from chemoimmunotherapy in the neoadjuvant setting.
Advancements in antibody drug conjugates, bispecific therapies, and other targeted agents may hold promise in lung cancer management.
A lower percentage of patients who were released within 1 year of incarceration received guideline-concurrent care vs incarcerated patients.
Stressing the importance of prompt AE disclosure before they become severe can ensure that a patient can still undergo resection with curative intent.
A collaboration between the Connecticut Departments of Health and Corrections and the COPPER Center aimed to improve outcomes among incarcerated patients.
Thomas Marron, MD, PhD, presented a session on clinical data that established standards of care for stage II and III lung cancer treatment at CFS 2025.
Related Content
Twice-daily radiotherapy prolongs survival vs once-daily radiation among those with LS-SCLC, even with the incorporation of immunotherapy.

Unraveling The Benefits of Twice-Daily Chemoradiotherapy in LS-SCLC

Russ Conroy
October 3rd 2025
Article

Twice-daily radiotherapy prolongs survival vs once-daily radiation among those with LS-SCLC, even with the incorporation of immunotherapy.

Experts highlight the top 5 presentations from ESMO 2025 that may have long-term clinical implications for genitourinary cancer management.

What Were The Most Impactful GU Oncology Data From ESMO 2025?

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD
November 6th 2025
Podcast

Experts highlight the top 5 presentations from ESMO 2025 that may have long-term clinical implications for genitourinary cancer management.

It may be possible to use anastrozole plus palbociclib, trastuzumab, and pertuzumab in place of chemotherapy in the frontline setting for hormone receptor–positive, HER2-positive metastatic breast cancer, says Amy Tiersten, MD.

Toxicity After Chemo May be Avoided With Anastrozole Combo in Breast Cancer

Amy Tiersten, MD
December 25th 2023
Article

It may be possible to use anastrozole plus palbociclib, trastuzumab, and pertuzumab in place of chemotherapy in the frontline setting for hormone receptor–positive, HER2-positive metastatic breast cancer, says Amy Tiersten, MD.

Experts highlight anticipated sessions at the 2025 ESMO Congress, including those on the PSMAddition and EV-303 trials.

Exploring the ESMO 2025 Presentations That May Shift GU Oncology

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD
October 16th 2025
Podcast

Experts highlight anticipated sessions at the 2025 ESMO Congress, including those on the PSMAddition and EV-303 trials.

Collaboration in kidney cancer palliative care and integrative medicine programs underscores the current development of University Hospitals’ integrative oncology wing.

Expert Outlines Collaborative Integrative Oncology Plans in Kidney Cancer

Santosh Rao, MD
April 10th 2023
Article

Collaboration in kidney cancer palliative care and integrative medicine programs underscores the current development of University Hospitals’ integrative oncology wing.